NASDAQ : EVAX
Evaxion A/S — Key statistics
Healthcare · Biotechnology · Denmark
Last price 2.9 USD (Oct 30, 2026, 3:45 PM EDT) · Market cap 24.19M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 24.35M |
| Enterprise Value | 17.46M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 8.34M |
| Shares Change (YoY) | +195.19% |
| Shares Change (QoQ) | -11.76% |
| Owned by Insiders (%) | 2.79% |
| Owned by Institutions (%) | 8.88% |
| Float | 5.68M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.25 |
| Forward PS | n/a |
| PB Ratio | 2.56 |
| P/TBV Ratio | 2.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.06 |
| Quick Ratio | 4.74 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.84 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -109.86% |
| Return on Assets (ROA) | -25.97% |
| Return on Invested Capital (ROIC) | -31.82% |
| Return on Capital Employed (ROCE) | -53.49% |
| Weighted Average Cost of Capital (WACC) | 7.54% |
| Revenue Per Employee | $162,848 |
| Profits Per Employee | -$188,152 |
| Employee Count | 46 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -941,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -49.22% |
| 50-Day Moving Average | 3.18 |
| 200-Day Moving Average | 3.49 |
| Relative Strength Index (RSI) | 42.76 |
| Average Volume (20 Days) | 128,944 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 67,048 |
| Short Previous Month | 50,577 |
| Short % of Shares Out | 0.89% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.51 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 7.49M |
| Gross Profit | 7.49M |
| Operating Income | -8.69M |
| Pretax Income | -9.60M |
| Net Income | -8.66M |
| EBITDA | -8.33M |
| EBIT | -8.69M |
| Loss Per Share | -$1.09 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 14.00M |
| Total Debt | 7.11M |
| Net Cash | 6.90M |
| Net Cash Per Share | $0.83 |
| Equity (Book Value) | 9.53M |
| Book Value Per Share | 1.14 |
| Working Capital | 12.73M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.16M |
| Capital Expenditures | -11,000 |
| Depreciation & Amortization | 365,000 |
| Net Borrowing | -742,000 |
| Free Cash Flow | -7.18M |
| FCF Per Share | -$0.86 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -116.02% |
| Pretax Margin | -128.10% |
| Profit Margin | -115.54% |
| EBITDA Margin | -111.15% |
| EBIT Margin | -116.02% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -195.19% |
| Shareholder Yield | -195.19% |
| Earnings Yield | -37.28% |
| FCF Yield | -29.46% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $12.25 |
| Price Target Difference | 319.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 10.93% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 14, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -8.02 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |